{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:14:47Z","timestamp":1775474087562,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10067-018-4332-7","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T10:54:02Z","timestamp":1539860042000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Role of comorbidities in spondyloarthritis including psoriatic arthritis"],"prefix":"10.1007","volume":"38","author":[{"given":"Silvia","family":"Scriffignano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Massimo","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"4332_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127\u20132137","journal-title":"Lancet"},{"key":"4332_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J et al (2009) The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"4332_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT et al (2011) The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25\u201331","journal-title":"Ann Rheum Dis"},{"key":"4332_CR4","doi-asserted-by":"publisher","unstructured":"Lubrano E, De Socio A, Perrotta FM (2017) Unmet needs in axial spondyloarthritis. Clin Rev Allergy Immunol. \n                    https:\/\/doi.org\/10.1007\/s12016-017-8637-0","DOI":"10.1007\/s12016-017-8637-0"},{"key":"4332_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/00325481.2018.1399774","volume":"130","author":"A Socio De","year":"2018","unstructured":"De Socio A, Perrotta FM, Grasso GM, Lubrano E (2018) Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of Central Italy: results of the CAMPO-RHE study. Postgrad Med 130:137\u2013141","journal-title":"Postgrad Med"},{"key":"4332_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/1744666X.2017.1327354","volume":"13","author":"E Lubrano","year":"2017","unstructured":"Lubrano E, Perrotta FM (2017) The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 13:815\u2013821","journal-title":"Expert Rev Clin Immunol"},{"key":"4332_CR7","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2147\/TCRM.S100091","volume":"12","author":"E Lubrano","year":"2016","unstructured":"Lubrano E, Perrotta FM (2016) Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag 12:1587\u20131592","journal-title":"Ther Clin Risk Manag"},{"key":"4332_CR8","first-page":"214","volume":"35","author":"E Lubrano","year":"2017","unstructured":"Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A (2017) A national survey on the management of psoriatic arthritis using the Delphi method. Clin Exp Rheumatol 35:214\u2013220","journal-title":"Clin Exp Rheumatol"},{"key":"4332_CR9","first-page":"991","volume":"35","author":"A Marchesoni","year":"2017","unstructured":"Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D\u2019Angelo S, Mathieu A et al (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35:991\u20131010","journal-title":"Clin Exp Rheumatol"},{"key":"4332_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3899\/jrheum.150805","volume":"43","author":"FM Perrotta","year":"2016","unstructured":"Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-\u03b1 drugs. J Rheumatol 43:350\u2013355","journal-title":"J Rheumatol"},{"key":"4332_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3899\/jrheum.140811","volume":"42","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Perrotta FM, Marchesoni A, D\u2019Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-\u03b1 drugs: an Italian multicenter study. J Rheumatol 42:258\u2013263","journal-title":"J Rheumatol"},{"key":"4332_CR12","first-page":"612","volume":"31","author":"C Papagoras","year":"2013","unstructured":"Papagoras C, Voulgari PV, Drosos AA (2013) Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 31:612\u2013620","journal-title":"Clin Exp Rheumatol"},{"key":"4332_CR13","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3899\/jrheum.161402","volume":"44","author":"R Scarpa","year":"2017","unstructured":"Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298\u20131301","journal-title":"J Rheumatol"},{"key":"4332_CR14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70:1921\u20131925","journal-title":"Ann Rheum Dis"},{"key":"4332_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/rheumatology\/ken198","volume":"47","author":"S Mathieu","year":"2008","unstructured":"Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima- media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47:1203\u20131207","journal-title":"Rheumatology (Oxford)"},{"key":"4332_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4081\/reumatismo.2013.105","volume":"65","author":"FM Perrotta","year":"2013","unstructured":"Perrotta FM, Scarno A, Carboni A, Bernardo V, Montepaone M, Lubrano E, Spadaro A (2013) Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices. Reumatismo 65:105\u2013112","journal-title":"Reumatismo"},{"key":"4332_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/ard.2009.116178","volume":"69","author":"JH Kang","year":"2010","unstructured":"Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69:1165\u20131168","journal-title":"Ann Rheum Dis"},{"key":"4332_CR18","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s10067-016-3362-2","volume":"35","author":"N Ahmed","year":"2016","unstructured":"Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL (2016) Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 35:3069\u20133073","journal-title":"Clin Rheumatol"},{"key":"4332_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00296-013-2927-5","volume":"34","author":"HH Chen","year":"2014","unstructured":"Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH (2014) Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int 34:265\u2013270","journal-title":"Rheumatol Int"},{"key":"4332_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/acr.20364","volume":"63","author":"S Mathieu","year":"2011","unstructured":"Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:557\u2013563","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4332_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/1744666X.2014.875468","volume":"10","author":"F Ingegnoli","year":"2014","unstructured":"Ingegnoli F, Gualtierotti R, Artusi C, Lubrano E (2014) Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. Expert Rev Clin Immunol 10:307\u2013315","journal-title":"Expert Rev Clin Immunol"},{"key":"4332_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s10067-012-2018-0","volume":"31","author":"MA Weijden van der","year":"2012","unstructured":"van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE (2012) High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 31:1529\u20131535","journal-title":"Clin Rheumatol"},{"key":"4332_CR23","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-011-1766-z","volume":"23","author":"MA Weijden van der","year":"2012","unstructured":"van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, Dijkmans BA, Heymans MW, Lems WF (2012) High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 23:1683\u20131690","journal-title":"Osteoporos Int"},{"key":"4332_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semarthrit.2017.12.001","volume":"48","author":"J Ram\u00edrez","year":"2017","unstructured":"Ram\u00edrez J, Nieto-Gonz\u00e1lez JC, Curbelo Rodr\u00edguez R, Casta\u00f1eda S, Carmona L (2017) Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48:44\u201352. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2017.12.001","journal-title":"Semin Arthritis Rheum"},{"key":"4332_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00223-017-0274-3","volume":"101","author":"C Pray","year":"2017","unstructured":"Pray C, Feroz NI, Haroon N (2017) Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int 101:182\u2013192","journal-title":"Calcif Tissue Int"},{"key":"4332_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","volume":"29","author":"PJ Mease","year":"2017","unstructured":"Mease PJ (2017) Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol 29:304\u2013310","journal-title":"Curr Opin Rheumatol"},{"key":"4332_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","volume":"77","author":"A Molt\u00f3","year":"2018","unstructured":"Molt\u00f3 A, Etcheto A, Gossec L, Boudersa N, Claudepierre P, Roux N, Lemeunier L, Martin A, Sparsa L, Coquerelle P, Soubrier M, Perrot S, Dougados M (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers\u2019 effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77:533\u2013540","journal-title":"Ann Rheum Dis"},{"key":"4332_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.semarthrit.2017.01.005","volume":"47","author":"A Fan","year":"2017","unstructured":"Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129\u2013132","journal-title":"Semin Arthritis Rheum"},{"issue":"2017","key":"4332_CR29","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/rheumatology\/kex318","volume":"57","author":"X Baraliakos","year":"2017","unstructured":"Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbasi-Zender E, Schmitz-Bortz E, Braun J (2017) Patients with fibromyalgia rarely fulfill classification criteria for axial spondyloarthritis. Rheumatology (Oxford) 57(2017):1541\u20131547. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex318","journal-title":"Rheumatology (Oxford)"},{"key":"4332_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24\u201331","journal-title":"Trends Immunol"},{"key":"4332_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/1756-185X.12456","volume":"20","author":"CYY Chan","year":"2017","unstructured":"Chan CYY, Tsang HHL, Lau CS, Chung HY (2017) Prevalence of depressive and anxiety disorders and validation of the hospital anxiety and depression scale as a screening tool in axial spondyloarthritis patients. Int J Rheum Dis 20:317\u2013325","journal-title":"Int J Rheum Dis"},{"key":"4332_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13075-014-0418-z","volume":"16","author":"JJ Meesters","year":"2014","unstructured":"Meesters JJ, Bremander A, Bergman S, Petersson IF, Turkiewicz A, Englund M (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16:418","journal-title":"Arthritis Res Ther"},{"key":"4332_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00296-010-1616-x","volume":"32","author":"I Ertenli","year":"2012","unstructured":"Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-\u03b1 antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323\u2013330","journal-title":"Rheumatol Int"},{"key":"4332_CR34","first-page":"839","volume":"32","author":"M Cutolo","year":"2014","unstructured":"Cutolo M, Paolino S, Pizzorni C (2014) Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol 32:839\u2013847","journal-title":"Clin Exp Rheumatol"},{"key":"4332_CR35","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3892\/ol.2017.6368","volume":"14","author":"CC Chang","year":"2017","unstructured":"Chang CC, Chang CW, Nguyen PA, Chang TH, Shih YL, Chang WY et al (2017) Ankylosing spondylitis and the risk of cancer. Oncol Lett 14:1315\u20131322","journal-title":"Oncol Lett"},{"key":"4332_CR36","doi-asserted-by":"publisher","unstructured":"Deng C, Li W, Fei Y, Li Y, Zhang F (2016) Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep 6. \n                    https:\/\/doi.org\/10.1038\/srep32063","DOI":"10.1038\/srep32063"},{"key":"4332_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14740338.2016.1238458","volume":"15","author":"S Bonovas","year":"2016","unstructured":"Bonovas S, Minozzi S, Lytras T, Gonz\u00e1lez-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F (2016) Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:35\u201354","journal-title":"Expert Opin Drug Saf"},{"key":"4332_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PC Kerkhof van de","year":"2016","unstructured":"van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF et al (2016) Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75:83\u201398","journal-title":"J Am Acad Dermatol"},{"key":"4332_CR39","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","volume":"41","author":"DD Gladman","year":"1998","unstructured":"Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103\u20131110","journal-title":"Arthritis Rheum"},{"key":"4332_CR40","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","volume":"69","author":"H Radner","year":"2017","unstructured":"Radner H, Lesperance T, Accortt NA, Solomon DH (2017) Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken) 69:1510\u20131518","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4332_CR41","doi-asserted-by":"publisher","unstructured":"Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature. \n                    https:\/\/doi.org\/10.1038\/nature05485","DOI":"10.1038\/nature05485"},{"key":"4332_CR42","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cyto.2015.04.004","volume":"75","author":"J Hutcheson","year":"2015","unstructured":"Hutcheson J (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:272\u2013279. \n                    https:\/\/doi.org\/10.1016\/j.cyto.2015.04.004","journal-title":"Cytokine"},{"key":"4332_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/jcm6070068","volume":"6","author":"M Chehimi","year":"2017","unstructured":"Chehimi M, Vidal H, Eljaafari A (2017) Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 6:68","journal-title":"J Clin Med"},{"key":"4332_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4081\/reumatismo.2017.953","volume":"69","author":"A Fassio","year":"2017","unstructured":"Fassio A, Gatti D, Gisondi P, Girolomoni G, Viapiana O, Giollo A (2017) Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo 69:105\u2013110. \n                    https:\/\/doi.org\/10.4081\/reumatismo.2017.953","journal-title":"Reumatismo"},{"key":"4332_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/acr.20363","volume":"63","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195\u2013202","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4332_CR46","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1136\/annrheumdis-2012-202325","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their cor- relation with disease activity. Ann Rheum Dis 72:1956\u20131961","journal-title":"Ann Rheum Dis"},{"key":"4332_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3899\/jrheum.150757","volume":"43","author":"M Haroon","year":"2016","unstructured":"Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43:463\u2013464","journal-title":"J Rheumatol"},{"key":"4332_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.160861","volume":"44","author":"L Eder","year":"2017","unstructured":"Eder L, Chandran V, Cook R, Gladman DD (2017) The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol 44:286\u2013291","journal-title":"J Rheumatol"},{"key":"4332_CR49","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2174\/138161282004140213123505","volume":"20","author":"AW Armstrong","year":"2014","unstructured":"Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:500\u2013512","journal-title":"Curr Pharm Des"},{"key":"4332_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.reuma.2013.07.006","volume":"10","author":"N Busquets","year":"2014","unstructured":"Busquets N, Vaquero CG, Moreno JR, Vilaseca DR, Narv\u00e1ez J, Carmona L, Nolla JM (2014) Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Reumatol Clin 10:89\u201393","journal-title":"Reumatol Clin"},{"key":"4332_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000413","volume":"3","author":"AM Gulati","year":"2017","unstructured":"Gulati AM, Hoff M, Salvesen \u00d8, Dhainaut A, Semb AG, Kavanaugh A, Haugeberg G (2017) Bone mineral density in patients with psoriatic arthritis: data from the Nord-Tr\u00f8ndelag health study 3. RMD Open 3:e000413","journal-title":"RMD Open"},{"key":"4332_CR52","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3899\/jrheum.110893","volume":"39","author":"A Marchesoni","year":"2012","unstructured":"Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A et al (2012) Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 39:849\u2013855","journal-title":"J Rheumatol"},{"key":"4332_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.semarthrit.2017.01.005","volume":"47","author":"A Fan","year":"2017","unstructured":"Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129\u2013132","journal-title":"Semin Arthritis Rheum"},{"key":"4332_CR54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","volume":"57","author":"A Marchesoni","year":"2018","unstructured":"Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H et al (2018) The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford) 57:32\u201340","journal-title":"Rheumatology (Oxford)"},{"key":"4332_CR55","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.151491","volume":"43","author":"S Brikman","year":"2016","unstructured":"Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749\u20131754","journal-title":"J Rheumatol"},{"key":"4332_CR56","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","volume":"41","author":"E McDonough","year":"2014","unstructured":"McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887\u2013896","journal-title":"J Rheumatol"},{"key":"4332_CR57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351\u2013360","journal-title":"Semin Arthritis Rheum"},{"key":"4332_CR58","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","volume":"31","author":"J Koo","year":"2017","unstructured":"Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ (2017) Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 31:1999\u20132009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4332_CR59","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","volume":"126","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126:2194\u20132201","journal-title":"J Invest Dermatol"},{"key":"4332_CR60","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","volume":"140","author":"G Frentz","year":"1999","unstructured":"Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140:237\u2013242","journal-title":"Br J Dermatol"},{"key":"4332_CR61","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s10067-016-3396-5","volume":"35","author":"KM Wilton","year":"2016","unstructured":"Wilton KM, Crowson CS, Matteson EL (2016) Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clin Rheumatol 35:2603\u20132607","journal-title":"Clin Rheumatol"},{"key":"4332_CR62","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G (2015) Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14:706\u2013714","journal-title":"J Drugs Dermatol"},{"key":"4332_CR63","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1007\/s10067-017-3885-1","volume":"36","author":"E Lubrano","year":"2017","unstructured":"Lubrano E, Perrotta FM (2017) Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 36:2633\u20132635","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4332-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T19:16:36Z","timestamp":1571339796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4332-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4332"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4332-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}